ReAlta lands $40m to back trial of first-in-class infant brain injury therapy

The biopharma will now look to accelerate the enrolment of infants into its mid-stage study on pegtarazimod in HIE.
Arabian Post

Funding lifts infant HIE drug race

Fresh financing for an experimental therapy targeting brain injury in newborns has sharpened attention on one of neonatal medicine’s hardest gaps: the absence of any approved drug for ...
MedPage Today

Adding Erythropoietin Did Not Reduce Death, Disability in Neonatal HIE

Adding a high dose of erythropoietin to therapeutic hypothermia did not reduce rates of death or disability in infants with neonatal hypoxic ischemic encephalopathy (HIE), a phase III randomized trial ...
Business Wire

ReAlta Life Sciences Publishes Data Demonstrating RLS-0071 (pegtarazimod) Reduces Brain Inflammation in Preclinical Hypoxic Ischemic Encephalopathy Model

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to ...
Rutland Herald

New Birth Injury Resource Center Launches as Data Shows Thousands of Newborns Face Preventable Complications Each Year

Freidin Brown, P.A., Releases Online Hub Providing Vital Information on Childbirth, Including a 5-Year Data-Driven Florida ...
KRON4 News

Co-occurrence of “Perinatal Stroke and Neonatal Hypoxic-ischemic Encephalopathy”

Study shows that perinatal arterial ischemic stroke often coexists with hypoxic-ischemic encephalopathy in infants receiving therapeutic hypothermia This article clearly shows that there are children ...